Plant Name: Curcuma wenyujin
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| TSHR; NPSR1; | |
| FAAH; TDP1; PTGES; TERT; NOS2; HPGD; ALOX15; ALDH1A1; USP2; BRCA1; | |
| TRPA1; | |
| PRKCE; GSK3B; MAPK1; EGFR; | |
| CA2; CA12; CA1; CA9; CA13; CA5B; CA7; CA4; CA6; | |
| PPARA; PPARD; PPARG; | |
| NR1I2; | |
| ALOX5; MAOA; PTGS1; | |
| KDM4E; | |
| BACE1; | |
| ANPEP; MMP9; | |
| TLR2; TLR9; | |
| HIF1A; TP53; | |
| EP300; | |
| HTT; NFE2L2; LMNA; FABP3; FABP5; F3; FABP2; FABP4; MAPT; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Bromodomain | EP300 | Histone acetyltransferase p300 | Q09472 | CHEMBL3784 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PTGES | Prostaglandin E synthase | O14684 | CHEMBL5658 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | NOS2 | Nitric oxide synthase, inducible | P35228 | CHEMBL4481 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | ANPEP | Aminopeptidase N | P15144 | CHEMBL1907 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | PRKCE | Protein kinase C epsilon | Q02156 | CHEMBL3582 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Toll-like and Il-1 receptors | TLR9 | Toll-like receptor 9 | Q9NR96 | CHEMBL5804 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NFE2L2 | Nuclear factor erythroid 2-related factor 2 | Q16236 | CHEMBL1075094 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.818E-11 | 1.800E-08 | ANPEP, BRCA1, CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9, EP300, MMP9, NR1I2, PPARA, PPARD, PPARG, TP53 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.792E-08 | 1.106E-05 | APP, BRCA1, CA2, CA9, CYP1A2, EGFR, HPGD, MAPK1, PPARG, PRKCE, PTGES, TLR2, TP53, TRPA1 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.899E-08 | 1.107E-05 | HIF1A, LMNA, NFE2L2, PPARD, PRKCE, TERT, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.881E-08 | 1.107E-05 | ALOX15, ALOX5, CYP19A1, CYP1A2, CYP2A6, CYP2C9, CYP2D6, NOS2 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.815E-08 | 1.362E-05 | CYP1A2, CYP2A6, CYP2C9, NR1I2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 1.080E-07 | 2.978E-05 | APP, TLR2, TLR9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.219E-07 | 3.198E-05 | CYP19A1, CYP1A2, CYP2A6, CYP2C9, CYP2D6, NOS2, PTGS1 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 5.379E-07 | 1.027E-04 | ALOX15, ALOX5, HPGD |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.379E-07 | 1.027E-04 | CYP1A2, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 8.064E-07 | 1.476E-04 | APP, CYP19A1, CYP1A2, CYP2A6, CYP2C9, CYP2D6, NR1I2, PPARD |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 9.465E-07 | 1.689E-04 | FABP2, FABP3, FABP4, FABP5 |
| CC | GO:0044464; cell part | GO:0005641; nuclear envelope lumen | 1.499E-06 | 2.531E-04 | ALOX5, APP, PTGES |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.533E-06 | 2.567E-04 | CA2, CA4, CA9, EGFR, HPGD, TLR9, TSHR |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.868E-06 | 2.991E-04 | FABP3, NOS2, PPARA, PPARD, PPARG |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 2.244E-06 | 3.417E-04 | APP, EGFR, MAPT |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.322E-06 | 3.421E-04 | CYP1A2, EGFR, MAPK1, MMP9 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 2.325E-06 | 3.421E-04 | EP300, GSK3B, HIF1A, HTT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 2.865E-06 | 4.105E-04 | BRCA1, CA2, EP300, MAPK1, PPARG |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.399E-06 | 4.807E-04 | CYP19A1, CYP2A6, CYP2C9, CYP2D6 |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 4.389E-06 | 5.758E-04 | GSK3B, HTT, MAPT |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 4.512E-06 | 5.813E-04 | FABP3, FFAR1, PPARG, PRKCE, TLR2 |
| MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 4.808E-06 | 6.087E-04 | NFE2L2, PPARA, TERT, TP53 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.565E-06 | 6.746E-04 | CA2, CA7, EGFR, HIF1A, HTT, MAPK1, NPSR1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.840E-06 | 6.987E-04 | CYP1A2, CYP2C9, CYP2D6 |
| BP | GO:0065007; biological regulation | GO:0032092; positive regulation of protein binding | 6.085E-06 | 7.162E-04 | APP, EP300, GSK3B, MMP9, TERT |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 7.575E-06 | 8.727E-04 | CA2, CA7, PRKCE |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.065E-05 | 1.126E-03 | CYP19A1, CYP1A2, CYP2C9, CYP2D6 |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.222E-05 | 1.267E-03 | APP, EGFR, MAPK1, TLR2, TLR9 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.286E-05 | 1.308E-03 | CA2, CA7, EGFR, HIF1A, HTT, MAPK1, NPSR1, PRKCE, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.474E-05 | 1.465E-03 | ALOX15, ALOX5, HPGD |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.501E-05 | 1.466E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.960E-05 | 1.824E-03 | EGFR, MAPK1, MMP9, NFE2L2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0090303; positive regulation of wound healing | 2.056E-05 | 1.897E-03 | F3, NFE2L2, PPARD, PRKCE |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 2.340E-05 | 2.123E-03 | BRCA1, EGFR, MAPK1, NFE2L2, NOS2, PRKCE, TP53 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 2.546E-05 | 2.290E-03 | CYP1A2, CYP2C9, CYP2D6, NR1I2, PTGS1 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.655E-05 | 2.360E-03 | CYP19A1, FFAR4, PPARA, PPARD, PPARG |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 2.746E-05 | 2.421E-03 | APP, TLR2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.746E-05 | 2.421E-03 | CA2, CA7 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 2.768E-05 | 2.431E-03 | EP300, GSK3B, NFE2L2, PPARA, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 3.152E-05 | 2.723E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0051704; multi-organism process | GO:0002237; response to molecule of bacterial origin | 3.189E-05 | 2.744E-03 | CYP1A2, HPGD, NOS2, PPARD, PTGES, TLR2, TLR9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.462E-05 | 2.933E-03 | CYP1A2, CYP2A6, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 4.000E-05 | 3.287E-03 | HIF1A, TERT, TP53 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 4.000E-05 | 3.287E-03 | HPGD, MMP9, TERT |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 4.063E-05 | 3.289E-03 | APP, GSK3B, NFE2L2, PPARG, TP53, TSHR |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 4.063E-05 | 3.289E-03 | CA2, CA7, HTT, NPSR1, PRKCE, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0032270; positive regulation of cellular protein metabolic process | 4.176E-05 | 3.368E-03 | ALOX15, APP, BRCA1, EGFR, F3, FFAR4, GSK3B, MAPK1, MAPT, MMP9, NFE2L2, PPARG, PRKCE, TLR9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.590E-05 | 3.661E-03 | CYP19A1, CYP1A2, CYP2D6 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 4.782E-05 | 3.800E-03 | BRCA1, NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 4.888E-05 | 3.870E-03 | CA2, CYP19A1, CYP1A2, EGFR, EP300, HIF1A, HPGD, HTT, MAPK1, PPARA, PPARD, PPARG, USP2 |
| BP | GO:0008152; metabolic process | GO:0036003; positive regulation of transcription from RNA polymerase II promoter in response to stress | 5.234E-05 | 4.115E-03 | HIF1A, NFE2L2, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0032741; positive regulation of interleukin-18 production | 5.482E-05 | 4.248E-03 | TLR2, TLR9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.482E-05 | 4.248E-03 | CYP1A2, CYP2C9 |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 5.525E-05 | 4.266E-03 | FFAR1, HIF1A, PPARD, PRKCE |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 5.935E-05 | 4.535E-03 | HIF1A, PPARD, TP53 |
| BP | Unclassified; | GO:0042346; positive regulation of NF-kappaB import into nucleus | 7.515E-05 | 5.566E-03 | APP, TLR2, TLR9 |
| BP | GO:0065007; biological regulation | GO:0043085; positive regulation of catalytic activity | 7.545E-05 | 5.569E-03 | ALDH1A1, APP, EGFR, F3, GSK3B, HIF1A, MAPK1, MAPT, NOS2, PPARG, PRKCE, TERT, TLR9, TSHR |
| BP | GO:0009987; cellular process | GO:1901522; positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 8.399E-05 | 6.096E-03 | EP300, HIF1A, NFE2L2 |
| BP | GO:0051179; localization | GO:0043269; regulation of ion transport | 8.924E-05 | 6.413E-03 | APP, CA2, CA7, FFAR1, HTT, MMP9, NPSR1, PRKCE, TLR9 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 9.118E-05 | 6.505E-03 | PPARA, PPARG |
| BP | GO:0065007; biological regulation | GO:0008217; regulation of blood pressure | 9.141E-05 | 6.505E-03 | ANPEP, NOS2, PPARA, PPARG, PTGS1 |
| BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 9.460E-05 | 6.624E-03 | EP300, GSK3B, MAPK1, MAPT |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 1.068E-04 | 7.383E-03 | BRCA1, F3, HIF1A, NFE2L2, TERT |
| BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 1.072E-04 | 7.385E-03 | APP, EGFR, FFAR4, GSK3B, HIF1A, LMNA, NFE2L2, PPARD, PPARG, TERT, TLR2, TLR9 |
| BP | GO:0050896; response to stimulus | GO:0031663; lipopolysaccharide-mediated signaling pathway | 1.145E-04 | 7.766E-03 | MAPK1, PRKCE, TLR2 |
| BP | GO:0008152; metabolic process | GO:0090322; regulation of superoxide metabolic process | 1.145E-04 | 7.766E-03 | EGFR, MAPT, NFE2L2 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.145E-04 | 7.766E-03 | ALOX15, ALOX5, TLR2 |
| CC | GO:0044464; cell part | GO:0030424; axon | 1.307E-04 | 8.647E-03 | APP, BACE1, CA2, HTT, MAPK1, MAPT |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 1.365E-04 | 8.926E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 1.365E-04 | 8.926E-03 | PPARA, PPARG |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 1.365E-04 | 8.926E-03 | FABP3, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.365E-04 | 8.926E-03 | CA1, CA2 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 1.412E-04 | 9.121E-03 | APP, CA4, EGFR, HTT, NOS2, PPARG, PRKCE, PTGES, USP2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.023E-20 | 1.312E-15 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.079E-15 | 5.872E-12 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.973E-15 | 3.346E-11 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.130E-19 | 3.579E-17 | CA12; CA1; CA5B; CA2; CA4; CA7; CA6; CA9; CA13 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.313E-09 | 7.353E-08 | CYP2C9; APP; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; PTGS1 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.260E-09 | 7.353E-08 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.240E-07 | 9.408E-06 | GSK3B; NOS2; EP300; MAPK1; PPARG; HIF1A; TP53; MMP9; EGFR; PPARD |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.069E-06 | 3.592E-05 | CYP2C9; ALOX5; ALOX15; PTGES; PTGS1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.828E-06 | 5.118E-05 | CYP2C9; CYP2A6; MAOA; CYP2D6; CYP1A2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.453E-06 | 1.355E-04 | GSK3B; EP300; MAPK1; TP53; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 6.375E-06 | 1.355E-04 | MAPK1; MMP9; TP53; EGFR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.319E-05 | 2.462E-04 | NOS2; EP300; MAPK1; HIF1A; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.663E-05 | 2.795E-04 | GSK3B; MAPK1; TP53; EGFR |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.924E-05 | 3.779E-04 | MAPK1; TP53; HIF1A; MMP9; EGFR; TLR2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.614E-05 | 3.660E-04 | PRKCE; EP300; MAPK1; BRCA1; TP53; MMP9; EGFR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.549E-05 | 3.660E-04 | GSK3B; EP300; MAPK1; TP53; HIF1A |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.526E-05 | 4.785E-04 | GSK3B; MAPK1; PPARA; TP53; EGFR |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 7.056E-05 | 6.586E-04 | EP300; MAPK1; TP53; MMP9; TLR2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.043E-05 | 4.785E-04 | CYP2C9; CYP2A6; CYP1A2; ALDH1A1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.557E-05 | 4.785E-04 | MAPK1; TP53; HIF1A; EGFR |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.386E-05 | 6.311E-04 | CYP2C9; CYP2A6; CYP2D6; CYP1A2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.244E-04 | 1.571E-03 | CYP2C9; CYP2A6; NOS2; MAOA; ANPEP; ALOX5; CYP1A2; ALOX15; ALDH1A1; CYP19A1; PTGS1; PTGES |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.367E-04 | 1.044E-03 | BACE1; APP; GSK3B; MAPK1; MAPT |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.791E-04 | 1.308E-03 | NOS2; TLR9; EP300; MAPK1; TLR2 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.951E-04 | 3.080E-03 | GSK3B; MAPK1; BRCA1; TP53; EGFR; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.521E-04 | 1.694E-03 | NOS2; TLR9; MAPK1; TLR2 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.080E-04 | 2.636E-03 | NOS2; ALOX5; MAPK1; TLR2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 6.968E-04 | 3.902E-03 | GSK3B; TLR9; TP53; TLR2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 8.189E-04 | 4.299E-03 | GSK3B; EP300; TP53; PPARD |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.049E-04 | 3.504E-03 | MAPK1; TP53; EGFR |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 8.437E-05 | 6.805E-04 | MAPK1; PPARG; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 6.049E-04 | 3.504E-03 | FABP4; TSHR; PTGS1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 9.354E-04 | 4.694E-03 | MAPK1; TP53; EGFR |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 8.150E-04 | 4.299E-03 | GSK3B; MAPK1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 9.778E-04 | 4.694E-03 | MAPK1; TP53; EGFR |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.964E-03 | 8.248E-03 | HPGD; PPARG; TP53; MMP9 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.437E-05 | 6.805E-04 | CYP2C9; CYP1A2; ALOX15 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.209E-03 | 5.640E-03 | MAPK1; TP53; EGFR |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 2.529E-03 | 9.655E-03 | HTT; EP300; PPARG; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 9.778E-04 | 4.694E-03 | EP300; MAPK1; HIF1A |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.169E-03 | 8.476E-03 | TLR9; EP300; TP53; TLR2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.824E-03 | 1.046E-02 | EP300; MAPK1; PPARA; TSHR |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.310E-03 | 5.947E-03 | NOS2; MAPK1; TLR2 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.168E-03 | 8.476E-03 | GSK3B; MAPK1; EGFR |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.362E-03 | 6.023E-03 | EP300; MAPK1; EGFR |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.311E-03 | 1.112E-02 | PRKCE; MAPK1; F3 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.129E-03 | 1.112E-02 | MAPK1; MMP9; EGFR |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 3.219E-03 | 1.112E-02 | GSK3B; EP300; MAPK1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.830E-03 | 7.884E-03 | CYP2C9; CYP2A6; CYP1A2 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.311E-03 | 1.112E-02 | MAPK1; HIF1A; EGFR |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.793E-03 | 1.249E-02 | TLR9; MAPK1; TLR2 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 6.785E-03 | 2.000E-02 | MAPK1; MAPT; TP53; EGFR |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.102E-03 | 1.325E-02 | GSK3B; PRKCE; PPARA |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 7.066E-03 | 2.029E-02 | GSK3B; TERT; EP300; TP53 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.363E-03 | 1.668E-02 | GSK3B; MAPK1; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.363E-03 | 1.668E-02 | PRKCE; MAPK1; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.200E-03 | 2.296E-02 | LMNA; MAPK1; TP53 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 5.873E-03 | 1.794E-02 | GSK3B; EP300; TP53 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 7.125E-03 | 2.029E-02 | EP300; MAPK1; EGFR |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.496E-02 | 3.643E-02 | GSK3B; EP300; MAPK1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.182E-02 | 4.822E-02 | GSK3B; EP300; TP53 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.182E-02 | 4.822E-02 | GSK3B; MAPK1; EGFR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.267E-02 | 4.945E-02 | EP300; MAPK1; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.966E-02 | 4.525E-02 | GSK3B; MAPK1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.916E-02 | 4.525E-02 | GSK3B; MAPK1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.966E-02 | 4.525E-02 | MAPK1; TP53 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 1.626E-02 | 3.903E-02 | EP300; MAPK1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.068E-02 | 4.696E-02 | NOS2; MAPK1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.357E-02 | 3.353E-02 | MAPK1; HIF1A |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.231E-02 | 3.132E-02 | MAPK1; PPARD |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.272E-02 | 3.190E-02 | CYP1A2; CYP19A1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.149E-02 | 2.970E-02 | GSK3B; TP53 |
| hsa05144 | Malaria_Homo sapiens_hsa05144 | 9.205E-03 | 2.494E-02 | TLR9; TLR2 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 8.846E-03 | 2.436E-02 | PRKCE; MAPK1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 9.570E-03 | 2.512E-02 | ALOX5; CYP19A1 |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 9.570E-03 | 2.512E-02 | NOS2; MAOA |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.210E-03 | 1.863E-02 | MAOA; CYP1A2 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 2.864E-03 | 1.046E-02 | MAPK1; EGFR |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.080E-03 | 8.476E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 8.507E-05 | 6.805E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; TLR2; TERT |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | EGFR; TLR2; TERT |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; EGFR |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; TLR9 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR; TLR9 |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR; APP |
| NA: NA | Geographic retinal atrophy | NA | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | TLR9 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TLR9; PTGS1; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; NOS2; FAAH; PTGS1 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | NFE2L2; EGFR; EGFR |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| I00-I99: Diseases of the circulatory system | Ischemic reperfusion injury | I00-I99 | PRKCE |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP; NPSR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; CA9; MAPK1; MMP9; EGFR; TLR2; TLR9 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; PPARD; NR1I2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; NOS2; TLR9; TLR9 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | TLR9 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; NOS2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; NOS2; PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | TLR9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | PRKCE; TLR9 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | NFE2L2; TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; FFAR1; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic kidney disease | E11.22 | NOS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | NOS2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | NOS2; TRPA1; FAAH; PTGS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; MMP9; EGFR; EGFR; TLR9; PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR; TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | TLR9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; EGFR; ANPEP |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Endotoxic shock | R57.8 | NOS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | TLR9 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | NOS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; TLR9 |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; EGFR; EGFR; EGFR; TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; EGFR |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; TERT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR; TLR2; TERT; F3 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; TLR9 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | TLR9 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TERT |
| C00-D49: Neoplasms | Cancer | C00-C96 | GSK3B; HIF1A; TP53; CA1; CA9; MAPK1; MMP9; EGFR; TLR2; APP; TLR9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; APP; PTGES; MAPT; PPARG; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; PTGS1 |